Loading patent…
AssigneePharma Mar, S.A.
InventorsCarmen Kahatt, José María Fernandez, Salvador Fudio, Arturo Soto, Pilar Lardelli
Estimating the term…
Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination with other anticancer drugs, in particular topoisomerase inhibitors. The invention further relates to the administration of lurbinectedin in combination with anti-emetic agents for effective control of symptoms related to nausea and vomiting, reduced lurbinectedin dosages to achieve a safer administration and an increase in the number of treatment cycles. Stable lyophilized formulations of lurbinectedin are also provided.
A method of treating a solid tumor selected from small cell lung cancer (SCLC), soft tissue sarcoma, Ewing sarcoma, synovial sarcoma, gastroenteropancreatic neuroendocrine tumors (GEP-NET), endometrial cancer, and glioblastoma, the method comprising administering lurbinectedin to a patient in need thereof, wherein lurbinectedin is administered in combination with irinotecan;
Dependencies are inferred from the claim text.